Anti-Human CD11a (Efalizumab)-Dylight® 488
Catalogue Number: 12-8013-ABO
| Manufacturer: | Abeomics |
| Type: | Recombinant Monoclonal |
| Alias: | ITGAL; integrin alpha L; LFA-1; LFA1A |
| Shipping Condition: | Blue Ice |
| Unit(s): | 50 ug |
| Host name: | Human |
| Clone: | hu1124 |
| Isotype: | IgG1, kappa |
| Immunogen: | Human CD11a |
| Application: | FA |
Description
Description: Expression Host : HEK-293 This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Efalizumab. Clone hu1124 recognizes human CD11a. This product is for research use only. CD11a and CD18 are the Integrin alpha-L and beta-2 subunits that combine to form LFA-1, a glycoprotein and a member of the Integrin family. The Integrin alpha-L/beta-2 complex is a receptor for ICAM1, ICAM2, ICAM3, ICAM4 and F11R. LFA-1 participates in the immunological synapses between CD8+ T lymphocytes and antigen-presenting cells. Efalizumab binds to the CD11a subunit of LFA-1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Anti-Human CD11a (Efalizumab) utilizes the same variable regions from the therapeutic antibody Efalizumab making it ideal for research projects.
Additional Text
Antibody Clonality
Monoclonal
Application Notes
The suggested concentration for Efalizumab biosimilar antibody for staining cells in flow cytometry is <= 1.0 µg per 106 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.
Storage Note
This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.
12-8013 Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations